Gery I, Zigler J S, Brady R O, Barranger J A
J Clin Invest. 1981 Nov;68(5):1182-9. doi: 10.1172/jci110363.
Although the enzymatic lesion in Gaucher's disease is well established, little is known concerning the pathogenic mechanisms involved in the clinical manifestations of the disease. In order to obtain insight into this unexplored aspect of Gaucher's disease, we examined the effects of glucocerebroside (GL(1)) at the cellular level in monolayers of cultured murine macrophages. The addition of GL(1) to these cultures stimulated the macrophages to release increased amounts of lymphocyte-activating factor (LAF) and lysosomal enzymes into the medium. These responses were proportional to the amount of GL(1) added to the culture. At higher levels of GL(1) (>/=20 mug/ml), lactic dehydrogenase, a cytoplasmic enzyme was also released indicating cellular damage at these doses. Intracellular LAF also increased in macrophages incubated with the high doses of GL(1), demonstrating an increase in total LAF production by these cells. Lipopolysaccharide acted synergistically with GL(1) and stimulated the release of exceedingly high levels of LAF which had a molecular weight profile similar to that of LAF released by exposure to lipopolysaccharide alone. Unlike GL(1), galactocerebroside, sphingomyelin, and ceramidetrihexoside, exerted little or no effect on the release of macrophage products. The effect of GL(1) was selective for macrophages since addition of this material to mouse lens epithelial cells had no detectable cytotoxic effect and it was only slightly toxic to lymphocytes or P815 cells in concentrations at which macrophages were clearly affected. A direct relationship was observed between the cytotoxicity of the sphingolipids and their accumulation in various cells. Macrophages accumulated large amounts of GL(1) but not sphingomyelin, whereas the other cells examined in this investigation did not accumulate either of these lipids. Human monocytes, like murine macrophages, also release increased amounts of LAF when incubated with GL(1). The effect of GL(1) was dose-responsive and synergy was found with lipopolysaccharide. The relevance of these findings to the pathogenesis of Gaucher's disease is considered.
尽管高雪氏病中的酶缺陷已明确,但对于该疾病临床表现所涉及的致病机制却知之甚少。为了深入了解高雪氏病这一未被探索的方面,我们在培养的小鼠巨噬细胞单层上,在细胞水平检测了葡萄糖脑苷脂(GL(1))的作用。向这些培养物中添加GL(1)刺激巨噬细胞向培养基中释放更多的淋巴细胞激活因子(LAF)和溶酶体酶。这些反应与添加到培养物中的GL(1)量成正比。在较高水平的GL(1)(≥20微克/毫升)时,细胞质酶乳酸脱氢酶也被释放出来,表明在这些剂量下细胞受到损伤。在与高剂量GL(1)孵育的巨噬细胞中,细胞内LAF也增加,表明这些细胞的总LAF产生增加。脂多糖与GL(1)协同作用,刺激释放出极高水平的LAF,其分子量分布与仅暴露于脂多糖时释放的LAF相似。与GL(1)不同,半乳糖脑苷脂、鞘磷脂和神经酰胺三己糖苷对巨噬细胞产物的释放几乎没有影响。GL(1)的作用对巨噬细胞具有选择性,因为将这种物质添加到小鼠晶状体上皮细胞中没有可检测到的细胞毒性作用,并且在明显影响巨噬细胞的浓度下,对淋巴细胞或P815细胞只有轻微毒性。观察到鞘脂的细胞毒性与其在各种细胞中的积累之间存在直接关系。巨噬细胞积累大量的GL(1)但不积累鞘磷脂,而在本研究中检测的其他细胞既不积累这两种脂质中的任何一种。人单核细胞与小鼠巨噬细胞一样,在与GL(1)孵育时也释放更多的LAF。GL(1)的作用具有剂量依赖性,并且发现与脂多糖有协同作用。讨论了这些发现与高雪氏病发病机制的相关性。